Milestones and Payments. In consideration of Seller’s grant of the exclusive distribution rights hereunder to Purchaser, Purchaser shall pay Seller the following amounts upon completion of the applicable milestone:
Milestones and Payments. On a Regeneron Target-by-Regeneron Target basis, Regeneron shall pay Intellia the milestone payments set forth in the table below upon the first achievement by Regeneron of the corresponding milestone event set forth in the table below for the first Regeneron Product Directed to such Regeneron Target. For clarity, each milestone event (and the corresponding milestone payment) is payable only once with respect to a given Regeneron Target (even if the same milestone event is subsequently achieved again for the same Regeneron Target, whether by the same Regeneron Product Directed to such Regeneron Target or by a different Regeneron Product Directed to such Regeneron Target).
Milestones and Payments. LLS and Company agree to the following provisions regarding timelines, Milestones and Payments in performance of the Research Program under the terms of the Agreement.
Milestones and Payments. 9.1 In consideration for the rights granted by Novartis to BMP in terms of this Agreement, BMP shall pay to Novartis under the following milestones:
9.1.1 USD2,000,000 (United States dollars two million ) within 30 calendar days after the Signing Date; and
9.1.2 USD 1,000,000 (United States dollars one million ) within 30 calendar days from the date of the official grant of the Registration. The above payments are non-refundable, except under the situation of clause 6.4 and clause 16.4 or in case Novartis breaches this Agreement as stipulated in Article 16.1.
9.2 BMP shall bear all the costs for, and expenses relating to, its activities under this Agreement, including but not limited to
9.2.1 the development and registration of the Product in the Field and in the Territory;
9.2.2 the clinical trials during the development and registration phase and during the Commercialization phase;
9.2.3 the Commercialization of the Product.
9.3 Any and all payments under this Agreement shall be made in United States dollars and are exclusive of value added tax, or similar tax as may be levied in the Territory. Novartis will be in charge of the business tax levied by the authority in the Territory.
9.4 BMP shall make the payments by money transfer into a bank account to be specified by Novartis, and against invoice that Novartis shall promptly issue.
9.5 All amounts due by BMP to Novartis in terms of or arising out of this Agreement, unless paid on due date, shall bear interest form due date to date of payment, calculated at a rate equivalent to the one year fixed term loan rate issued by the Central Bank of China plus 10%, or the maximum rate permitted by applicable law, whichever is less. If the payment is overdue for 3 months, Novartis shall have the right to terminate the Agreement. The right of termination of this Agreement under this clause 9.5 does not apply to the disputed payment that has been submitted for arbitration under Article 18.
9.6 Upon the termination of this Agreement for any reason (except for the defaults by Novartis under 16.1) , all amounts then owing by BMP to Novartis shall immediately become due, owing and payable.
9.7 All amounts payable by BMP to Novartis in terms of this Agreement shall be made without deduction or set-off and BMP shall not be entitled, for any reason whatsoever, to withhold or defer any payment.
Milestones and Payments. In consideration of Seller’s grant of the exclusive distribution rights hereunder to Purchaser, Purchaser shall pay Seller the sum of $4,500,000 upon the Effective Date of this Agreement.”
Milestones and Payments. EYETECH and ARCHEMIX will each make the following payments to the other upon the first achievement by it of the following milestone events with respect to each VEGF Product : Milestone (in US Dollars)
(a) [***] $ [***]
(b) [***] $ [***]
(c) [***] $ [***]
(d) [***] $ [***]
(e) [***] $ [***]
(f) [***] $ [***] The Party developing the VEGF Product shall immediately notify the other Party of the achievement of the above milestone events with respect to each VEGF Product; provided that if a payment is made for Milestone (b), (c), (d), (e) or (f) with respect to a VEGF Product and any of the preceding Milestone payments were not made with respect to such VEGF Product, such earlier Milestone payments shall be made concurrently therewith (e.g., if Milestone (d) is achieved, but Milestone (c) was never achieved or paid, the payments for Milestone (c) and (d) shall be made concurrently). For the avoidance of doubt, in no event shall any of the foregoing milestones be paid [***] by either Party for any VEGF Product, even if such VEGF Product is approved or utilized for different Indications than first approved or utilized.
Milestones and Payments. EYETECH will make the following payments to ARCHEMIX upon the first achievement of the following milestone events with respect to each Compound or Back-Up, other than Compounds or Back-ups against VEGF:
(A) [***]. $ [***]
(B) [***] $ [***]
(C) [***] $ [***]
(D) [***] $ [***]
(E) [***] $ [***]
(F) [***] [***] $ [***]
(G) [***] $ [***]
(H) [***] $ [***] Confidential Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. EYETECH shall immediately notify ARCHEMIX of the achievement of the above milestone events with respect to each Compound; provided that if a payment is made for Milestone (B), (C), (D), (E) or (F) with respect to a Compound and any of the preceding Milestone payments were not made with respect to such Compound, such earlier Milestone payments shall be made concurrently therewith (e.g. if Milestone (F) is achieved, but Milestone (E) was never achieved or paid, the payments for Milestone (E) and (F) shall be made concurrently). For the avoidance of doubt, in no event shall any of the foregoing milestones be paid more than once for any Compound, even if such Compound is approved or utilized for different Indications than first approved or utilized.
Milestones and Payments. LLS and Affimed agree to the following provisions regarding Milestones and payments in performance of the AFM13 Development Program under the terms of the Agreement. M1 ***** ***** ***** M2 ***** ***** ***** M3 ***** ***** ***** M4 ***** ***** ***** M5* ***** ***** ***** M6* ***** ***** ***** M7* ***** ***** ***** All milestone payments shall become due and payable by LLS within ***** after LLS’ receipt of a written notice from Affimed confirming that the respective milestone event has occurred. * For clarification: Milestones M5 - M7 are each dependent on ***** as further described in the Affimed Proposal (Exhibit D). If no regimen *****, LLS reserves the right to make a No-go funding decision and cease all payments of Milestones M5 - M7.
Milestones and Payments. LLS and Company agree to the following provisions regarding timelines, Milestones and Payments in performance of the Research Program under the terms of the Agreement. [**]. Development of [**], an inhibitor of BET protein bromodomains, for the treatment of patients with hematologic malignancies Disease Diagnostic Group ☒ Lymphoma ☒ Leukemia ☒ Myeloma ☐ Other ☐ Not Assignable Specific Disease (if assignable) Patients with lymphoma, myeloma or acute leukemia Technology ☒ Small Molecule Therapeutic ☐ Delivery Technology ☐ Biological Therapeutics ☐ Medical Device ☐ Device/Diagnostic ☐ Other Current Stage of Project [**]. Target / Pathway / Mechanism of Action [**]. Total Funding Requested and Timeframe 7.5 million USD is requested. [**]. Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 11 pages were omitted. [**]
Milestones and Payments. The Commonwealth will make payments subject to performance reporting demonstrating the relevant milestone has been met. After the initial payment, second and subsequent milestone payments will be assessed and processed in the following reporting period. Performance reporting will be due by 31 March and 30 September each year until the cessation of this Agreement, or the final milestone is processed. As part of the performance reporting, SA will provide evidence of what has been delivered in the reporting period. Payments will be processed once performance reports have been assessed and accepted.
